Deo Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.99 M
- Company Age 20 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.17 Cr
- Revenue Growth 43.84%
- Profit Growth -32.87%
- Ebitda -55.97%
- Net Worth -12.11%
- Total Assets -11.38%
About Deo Pharmaceuticals
Deo Pharmaceuticals Private Limited (DPPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 December 2004 and has a history of 20 years and two months. Its registered office is in Tiruvallur, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.99 M.
The company currently has active open charges totaling ₹1.17 Cr.
Somasekharan Sureshbabu and Ramalingaiyar Sadhanantham serve as directors at the Company.
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231TN2004PTC054831
- Company No.
054831
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Dec 2004
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Deo Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Somasekharan Sureshbabu  | Director | 06-Dec-2004 | Current |
| Ramalingaiyar Sadhanantham | Director | 12-Jan-2007 | Current |
Financial Performance of Deo Pharmaceuticals.
Deo Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 43.84% increase. The company also saw a substantial fall in profitability, with a 32.87% decrease in profit. The company's net worth observed a substantial decline by a decrease of 12.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Deo Pharmaceuticals?
In 2023, Deo Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹11.68 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of Travancore : 0.68 Cr
- State Bank Of India : 0.49 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Nov 2019 | State Bank Of India | ₹4.90 M | Open |
| 23 Mar 2010 | State Bank Of Travancore | ₹0.72 M | Open |
| 08 Aug 2007 | State Bank Of Travancore | ₹0.61 M | Open |
| 02 Jun 2007 | State Bank Of Travancore | ₹4.70 M | Open |
| 26 May 2007 | State Bank Of Travancore | ₹0.75 M | Open |
How Many Employees Work at Deo Pharmaceuticals?
Unlock and access historical data on people associated with Deo Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Deo Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Deo Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
